Page 3 - Cadila Health News Today : Breaking News, Live Updates & Top Stories | Vimarsana

جريدة الجريدة الكويتية | «كاديلا» الهندية تعتزم اختبار لقاح مضاد لسلالات «كورونا» المتحورة

جريدة الجريدة الكويتية | «كاديلا» الهندية تعتزم اختبار لقاح مضاد لسلالات «كورونا» المتحورة
aljarida.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aljarida.com Daily Mail and Mail on Sunday newspapers.

Cadila healthFinancial expressPatel directorAhmad hyderabadகாடிலா ஆரோக்கியம்நிதி எக்ஸ்பிரஸ்படேல் இயக்குனர்

Can Virafin be a viable alternative for Remdesivir as COVID-19 wreaks havoc in India

The price of the drug is yet to be decided but it will be positioned competitively against Remdesivir

Zydus cadilaSharvil patelCadila healthCadila healthcareDrugs controller generalManaging directorCadila healthcare limitedRemdesivir injectionCovid 19ஜய்துச் காடிலாஷார்வில் படேல்காடிலா ஆரோக்கியம்காடிலா சுகாதாரம்மருந்துகள் கட்டுப்படுத்தி ஜநரல்நிர்வகித்தல் இயக்குனர்காடிலா சுகாதாரம் வரையறுக்கப்பட்டவை

Zydus Virafin gets emergency use approval for treating moderate COVID-19 cases

Zydus Virafin gets emergency use approval for treating moderate COVID-19 cases ANI | Updated: Apr 23, 2021 16:04 IST New Delhi [India], April 23 (ANI): The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila s Pegylated Interferon alpha-2b, Virafin for treating moderate COVID-19 infection in adults. A release by Cadila Health said, The drug has also shown efficacy against other viral infections. Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited said: The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19.

New delhiSharvil patelCadila healthCadila healthcareDrugs controller generalZydus cadilaPegylated interferonManaging directorCadila healthcare limitedZydus cadilaPegylated interferonCovid 19புதியது டெல்ஹிஷார்வில் படேல்காடிலா ஆரோக்கியம்காடிலா சுகாதாரம்

Market Movers: Cadila soars on Covid drug nod; 71 stocks give buy signals

Market Movers: Cadila soars on Covid drug nod; 71 stocks give buy signals SECTIONS Share Synopsis As many as 72 stocks listed on the National Stock Exchange gave buy signals based on MACD. Names include Motherson Sumi, Reliance Industries, PVR, Maruti Suzuki India, and Inox Leisure. Shutterstock.com For the day, Nifty50 ended 0.5 per cent, or 64.8 points, lower at 14,351.35, while Sensex closed at 47,878.45, down 202 points or 0.4 per cent. Related MUMBAI: Benchmark equity indices ended the day in red as investors booked profits towards the close of the session as they were reluctant to carry their positions to the next week in light of the uncertainty created by the second wave of COVID-19 pandemic.

Cadila healthReliance industriesNational stock exchangeNazara technologiesMaruti suzuki indiaCadila sharesShare market latest updateDr reddys sharesStock marketStock market newsNazara sharesகாடிலா ஆரோக்கியம்நம்பகத்தன்மை தொழில்கள்தேசிய ஸ்டாக் பரிமாற்றம்நஜரா தொழில்நுட்பங்கள்மாருதி ஸஸூகீ இந்தியா

DGCI approves emergency use of Zydus s Virafin in treating moderate COVID-19 infection

DGCI approves emergency use of Zydus s Virafin in treating moderate COVID-19 infection ANI | Updated: Apr 23, 2021 16:36 IST By Joymala Bagchi New Delhi [India], April 23 (ANI): Zydus Cadila received emergency use approval from the Drugs Controller General of India (DGCI) on Friday for the use of Virafin , Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults. A single-dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID-19, Virafin will help patients recover faster and avoid much of the complications, the company said. In a release, Cadila Health highlighted that the drug has also shown efficacy against other viral infections.

New delhiJoymala bagchiZydus cadilaSharvil patelCadila healthCadila healthcareDrugs controller generalPegylated interferonManaging directorCadila healthcare limitedEmergency use approvalபுதியது டெல்ஹிஜய்துச் காடிலாஷார்வில் படேல்காடிலா ஆரோக்கியம்காடிலா சுகாதாரம்